Aarti Pharmalabs Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Aarti Pharmalabs Ltd is ₹ 641.25 as of 12 Jun 15:30 . The P/E Ratio of Aarti Pharmalabs Ltd changed from 18.2 on March 2024 to 12.9 on March 2023 . This represents a CAGR of -6.65% over 5 yearsThe P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years The Market Cap of Aarti Pharmalabs Ltd changed from ₹ 3942 crore on March 2024 to ₹ 2489 crore on March 2023 . This represents a CAGR of -8.79% over 5 yearsThe Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 years The revenue of Aarti Pharmalabs Ltd for the Mar '26 is ₹ 596.21 crore as compare to the Dec '25 revenue of ₹ 436.83 crore. This represent the growth of 36.49% The revenue of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 13.81 crore as compare to the Dec '25 revenue of ₹ 22.36 crore. This represent the decline of -38.24% The ebitda of Aarti Pharmalabs Ltd for the Mar '26 is ₹ 126.7 crore as compare to the Dec '25 ebitda of ₹ 104.07 crore. This represent the growth of 21.74% The ebitda of Sanjivani Paranteral Ltd for the Mar '26 is ₹ 2.17 crore as compare to the Dec '25 ebitda of ₹ 4.13 crore. This represent the decline of -47.46% The net profit of Aarti Pharmalabs Ltd changed from ₹ 55.45 crore to ₹ 61.12 crore over 8 quarters. This represents a CAGR of 4.99% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 0.55 crore over 8 quarters. This represents a CAGR of -43.29% The Dividend Payout of Aarti Pharmalabs Ltd changed from 10.55 % on March 2023 to 17.61 % on March 2025 . This represents a CAGR of 18.62% over 3 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Aarti Pharmalabs Ltd

Aarti Pharmalabs Limited was initially incorporated as 'Aarti Organics Limited' in 2019.
The name of the Company was changed to Aarti Pharmachem Limited from Aarti Organics Limited' in July, 2021 and to Aarti Pharmalabs Limited in 2022.
Company is a manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India.
It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anti-cancer, Anti-Asthma, Anti-Hypertensive etc. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Aarti Pharmalabs Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Aarti Pharmalabs Ltd or Sanjivani Paranteral Ltd?

Market cap of Aarti Pharmalabs Ltd is 5,813 Cr while Market cap of Sanjivani Paranteral Ltd is 181 Cr

What are the key factors driving the stock performance of Aarti Pharmalabs Ltd and Sanjivani Paranteral Ltd?

The stock performance of Aarti Pharmalabs Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarti Pharmalabs Ltd and Sanjivani Paranteral Ltd?

As of June 15, 2026, the Aarti Pharmalabs Ltd stock price is INR ₹641.25. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹147.4.

How do dividend payouts of Aarti Pharmalabs Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Aarti Pharmalabs Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.